PMI news

NYSE American accepted Picard Medical's plan to regain continued listing standards, extending the compliance period through November 2027. This decision protects the company's listing and allows it to continue executing its strategic growth initiatives.

Richard Fang assumed the role of Interim CEO following Patrick's departure, and the company reported a 85% year-over-year revenue increase. This update highlights strong operational momentum and manufacturing progress despite the leadership transition.

Picard Medical announced its stockholder presentation, highlighting strong revenue growth and an 85% year-over-year increase. The release provides investors with key business updates regarding financial performance and product development ahead of the annual meeting.

Picard Medical appointed Chairman Richard Fang as interim CEO following the resignation of Patrick Schnegelsberg. The medical device developer is seeking a permanent replacement for its synthetic heart division.

Picard Medical achieved $1.2M in Q1 2026 revenue with 24% gross margins and reduced debt by $9.5M. The artificial heart maker is making progress toward profitability after its 2025 IPO that raised $17.4M.

Picard Medical turned gross profit positive with 85% revenue growth to $1.2M in Q1 2026 while reducing debt by $10.4M through cash repayment and stock settlement. The company raised $5.0M in May 2026 offering and restructured warrants to strengthen capital structure amid NYSE American listing compli…